Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.
about
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceStem cell therapy for diabetes mellitusConcise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 DiabetesGenetics, pathogenesis and clinical interventions in type 1 diabetesType 1 diabetes: translating mechanistic observations into effective clinical outcomesCellular islet autoimmunity associates with clinical outcome of islet cell transplantation.Immunotherapy of type 1 diabetes: where are we and where should we be going?The road not taken: a path to curing type 1 diabetes?Efforts to prevent and halt autoimmune beta cell destruction.The use of FK 506 in new-onset type I diabetes in man.A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease.Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Noninsulin pharmacological management of type 1 diabetes mellitusImmune intervention in type 1 diabetes.Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporinImmune interventions to preserve β cell function in type 1 diabetesTranslational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.George S. Eisenbarth: insulin and type 1 diabetes.Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocolNew potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the futureThe role of immunomodulation therapy in autoimmune diabetesTeplizumab therapy for type 1 diabetes.Clinical immunologic interventions for the treatment of type 1 diabetes.Progress in immune-based therapies for type 1 diabetes.Role of immune system modulation in prevention of type 1 diabetes mellitus.Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model.Type 1 diabetes pathogenesis - Prevention???Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantationLow-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 Diabetes
P2860
Q26850621-90496C71-28D4-4A9D-AE66-F8C2A7BB70A7Q27011453-2A285090-1BFB-4F76-9FE6-FCD4C4933554Q28071490-BEDF2216-3DF6-4CEA-849A-A2864F132C6CQ28281029-C3310E98-A392-4AD6-BF0D-938FB4B10A7DQ28287737-CCC3A081-32FB-439E-BC0D-3047BF70C9B7Q33344421-72C6712C-35CA-4225-8931-EF430347C560Q33815506-7EDF0B53-39FF-4657-BBF2-D36C17C47EB0Q33859301-FB599D59-FAF3-4927-BCFA-4AD574035F5BQ34077363-11F21A01-436F-4DE4-ACE9-92F4EEE33037Q34346734-583BF37A-497C-4F47-8B13-D7C679D3AA68Q34421851-EE201CD1-15C7-44C0-A563-9D2EC75B727EQ35108159-DFE90109-207B-4DD4-856A-CA539F592940Q35116303-666B38CF-9BA1-4D52-BD06-02D6A32E8274Q35153044-6F68C478-C8F6-4B6D-8D7C-39C0EF56EC1BQ35226251-42B04817-B1B3-4FC6-B640-AD796628C265Q35612633-DC2C81C8-370F-4121-BC92-8FCCFC2B0E1AQ35751049-751FCA5C-1D4C-4211-8875-5157C95D0109Q36520618-C8AABE74-327D-4E96-AA49-6AB4636B43DAQ36755915-E8D8EC81-8219-4FD8-B17B-E29B0008CE16Q36868176-DDC85A5D-11CE-4D84-8EEB-9E880EB94011Q36908165-FB0D238C-7533-4553-9FED-4D13FB0E1F89Q36913132-7CEA59C9-733A-46DF-BD7E-9817CDC7E803Q37031038-050B42C9-BCBA-4A43-9055-74D47C0DBAC7Q37240506-A36A6855-0E4A-430B-97F3-EE0E34292E86Q37360439-BAF0E747-0A39-4FAA-8868-AEDA0B771459Q37364899-97D489D0-6946-44A2-BAFE-20AEB63F7BD5Q37408019-D36DF1EB-2542-4650-851F-10E8EBA13971Q37679927-3F99B56F-E9CD-4352-9354-24B8900C2C10Q38036230-F338FEE5-5176-49AC-B7C0-FCBB46C99F10Q38097920-B308F6FF-9E4E-43DB-8E2E-5F664F06FB56Q39505919-9E06C779-CF46-4F23-B650-CC8163941E8BQ39793666-B86C3D27-2842-4085-99AD-FA3839E28F35Q40042478-B028E1E1-3BAA-468B-8884-BE241582F6E9Q56787009-429D575E-F4C5-4762-8593-259C71F3B62BQ57163295-DC7B815A-2C7A-476F-B6AB-7BC5A8A9CDA6
P2860
Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.
description
1985 nî lūn-bûn
@nan
1985 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Anti-thymocyte globulin and pr ...... nset type 1 diabetes mellitus.
@ast
Anti-thymocyte globulin and pr ...... nset type 1 diabetes mellitus.
@en
type
label
Anti-thymocyte globulin and pr ...... nset type 1 diabetes mellitus.
@ast
Anti-thymocyte globulin and pr ...... nset type 1 diabetes mellitus.
@en
prefLabel
Anti-thymocyte globulin and pr ...... nset type 1 diabetes mellitus.
@ast
Anti-thymocyte globulin and pr ...... nset type 1 diabetes mellitus.
@en
P2093
P1476
Anti-thymocyte globulin and pr ...... onset type 1 diabetes mellitus
@en
P2093
Eisenbarth GS
Rabinowe S
Srikanta S
P304
P577
1985-11-01T00:00:00Z